Is it safe?
Can XERS take a bad year?
Xeris Biopharma Holdings, Inc. carries $109M of net debt at 2.61× EBITDA: a load its earnings can carry.
$109M
Net debt · as at Q1 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 2.61×
Net debt / EBITDA
- Altman Z-score
- 1.01
Altman Z-score · distress zone, below 1.8
- Interest cover
- 1.25×
Interest cover · operating profit barely covers the interest bill
Details›
- Total debtQ1 2026
- $221M
- Cash and short-term investments
- $112M
- Net debt
- $109M
- EBITDA, trailing twelve months
- $42M
- Operating profit, trailing twelve months
- $36M
- Debt / equity
- 17.0×
- Total debt / EBITDA
- 5.27×
- Annualised volatilitytwo years of daily moves
- 56%
- Worst drawdown on file
- −96%
- Below its 52-week high
- −12%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers - Specialty & Generic
Ranks #12 of 28 by Smart Score